Pharmacokinetic and pharmacodynamic analysis revealed robust MYC repression at 2, 4 and 8 hr following acute AZD5153 administration, supporting MYC modulation as an on-target anti-tumor mechanism in this model (S5D Fig). This evidence concerns the gene MYC and neoplasm.